SAN

78.69

-1.87%↓

UCB

263.9

+0.8%↑

SHL.DE

40.6

-1.31%↓

ARGX

648.4

-0.25%↓

PHIA

26.15

-0.49%↓

SAN

78.69

-1.87%↓

UCB

263.9

+0.8%↑

SHL.DE

40.6

-1.31%↓

ARGX

648.4

-0.25%↓

PHIA

26.15

-0.49%↓

SAN

78.69

-1.87%↓

UCB

263.9

+0.8%↑

SHL.DE

40.6

-1.31%↓

ARGX

648.4

-0.25%↓

PHIA

26.15

-0.49%↓

SAN

78.69

-1.87%↓

UCB

263.9

+0.8%↑

SHL.DE

40.6

-1.31%↓

ARGX

648.4

-0.25%↓

PHIA

26.15

-0.49%↓

SAN

78.69

-1.87%↓

UCB

263.9

+0.8%↑

SHL.DE

40.6

-1.31%↓

ARGX

648.4

-0.25%↓

PHIA

26.15

-0.49%↓

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

81.95 0.61

Résumé

Variation du prix de l'action

24h

Actuel

Min

79.9

Max

82.25

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

34.705

66.845

BPA

1.135

Marge bénéficiaire

19.539

Employés

2,197

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.43% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

230M

4.2B

Ouverture précédente

81.34

Clôture précédente

81.95

Sentiment de l'Actualité

By Acuity

50%

50%

162 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mars 2026, 23:39 UTC

Actions en Tendance

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mars 2026, 23:20 UTC

Résultats

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mars 2026, 21:43 UTC

Résultats

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mars 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mars 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mars 2026, 22:30 UTC

Résultats

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mars 2026, 22:30 UTC

Résultats

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mars 2026, 22:30 UTC

Résultats

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mars 2026, 22:13 UTC

Résultats

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mars 2026, 22:13 UTC

Résultats

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mars 2026, 22:13 UTC

Résultats

Vermilion Energy 4Q EPS C$2.86 >VET

4 mars 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mars 2026, 21:53 UTC

Résultats

Lithium Americas 4Q Rev $66.8M >LAC

4 mars 2026, 21:53 UTC

Résultats

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mars 2026, 21:52 UTC

Résultats

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mars 2026, 21:50 UTC

Résultats

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mars 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 mars 2026, 21:48 UTC

Résultats

Webull 4Q Rev $165.2M >BULL

4 mars 2026, 21:48 UTC

Résultats

Webull 4Q EPS 1c >BULL

4 mars 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 mars 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mars 2026, 21:40 UTC

Résultats

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mars 2026, 21:36 UTC

Principaux Événements d'Actualité

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mars 2026, 21:27 UTC

Résultats

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mars 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mars 2026, 21:16 UTC

Résultats

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mars 2026, 21:15 UTC

Résultats

Broadcom 1Q EPS $1.50 >AVGO

4 mars 2026, 21:15 UTC

Résultats

Broadcom 1Q Net $7.35B >AVGO

4 mars 2026, 21:15 UTC

Résultats

Broadcom 1Q Rev $19.31B >AVGO

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

10.43% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  10.43%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

162 / 351Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat